We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GUIDANCE ISSUED ON PRODUCTS TO TREAT ULCERS AND BURN WOUNDS

GUIDANCE ISSUED ON PRODUCTS TO TREAT ULCERS AND BURN WOUNDS

June 12, 2006

The FDA published a guidance for industry on developing drugs and biologic treatments for ulcers and burn wounds.

The guidance provides recommendations on developing products to treat chronic cutaneous ulcers -- including venous stasis ulcers, diabetic foot ulcers and pressure ulcers -- and burn wounds. It includes general guidance on clinical trial design, such as recommendations for trial design, labeling claims, outcome measures and special considerations for preclinical development and manufacturing.

The guidance defines a chronic cutaneous ulcer as a "wound that has failed to proceed through an orderly and timely series of events to produce a durable structural, functional and cosmetic closure"; and a burn wound as "a cutaneous wound induced by thermal, chemical or electrical injury."

The "Guidance for Industry on Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment" can be viewed at http://www.fda.gov/OHRMS/DOCKETS/98fr/00d-1318-gdl0002.pdf (http://www.fda.gov/OHRMS/DOCKETS/98fr/00d-1318-gdl0002.pdf).

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Updates Smiths Medical CADD System Recall to Class I

  • Eisai’s New Alzheimer’s Drug Leqembi Hits the U.S. Market

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing